Systemic antiviral immunization by virus-mimicking nanoparticles-decorated erythrocytes
Source abstract
Abstract
New vaccine technologies are urgently needed to produce safe and effective vaccines in a more timely manner to prevent future infectious disease pandemics. Here, we describe erythrocyte-mediated systemic antiviral immunization, a versatile vaccination strategy that boosts antiviral immune responses by using erythrocytes decorated with virus-mimetic nanoparticles carrying a viral antigen and a Toll-like receptor (TLR) agonist. As a proof of concept, polydopamine nanoparticles were synthesized via a simple in situ polymerization in which the nanoparticles were conjugated with the SARS-CoV-2 spike protein S1 subunit and the TLR7/8 agonist R848. The resulting SARS-CoV-2 virus-mimetic nanoparticles were attached to erythrocytes via catechol groups on the nanoparticle. Erythrocytes naturally home to the spleen and interact with the immune system. Injection of the nanoparticle-decorated erythrocytes into mice resulted in greater maturation and activation of antigen-presenting cells, humoral and cellular immune responses in the spleen, production of S1-specific immunoglobulin G (IgG) antibodies, and systemic antiviral T cell responses than a control group treated with the nanoparticles alone, with no significant negative side effects. These results show that erythrocyte-mediated systemic antiviral immunization using viral antigen- and TLR agonist-presenting polydopamine nanoparticles-a generalizable method applicable to many viral infections-is effective new approach to developing vaccines against severe infectious diseases.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Respiratory viral infections research · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Duration of antiviral immunity after smallpox vaccination10.1038/nm917 ↗
2. A blueprint for HIV vaccine discovery10.1016/j.chom.2012.09.008 ↗
3. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus10.3389/fmicb.2019.01781 ↗
4. WHO, https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19–13-april-2021, 2020.
5. Sensitive, rapid, low-cost, and multiplexed COVID-19 monitoring by the wireless telemedicine platform10.1016/j.matt.2020.11.001 ↗
6. Covid-19: four fifths of cases are asymptomatic, China figures indicate10.1136/bmj.m1375 ↗
7. COVID-19 vaccine development and a potential nanomaterial path forward10.1038/s41565-020-0737-y ↗
8. Engineering antiviral vaccines10.1021/acsnano.0c06109 ↗
9. Evolutionary reversion of live viral vaccines: can genetic engineering subdue it?10.1093/ve/vev005 ↗
10. Vaccine adjuvants: putting innate immunity to work10.1016/j.immuni.2010.10.002 ↗
11. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity10.4049/jimmunol.172.10.6290 ↗
12. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells10.4049/jimmunol.161.8.4023 ↗
13. Interactions of engineered nanoparticles with organs protected by internal biological barriers10.1002/smll.201201463 ↗
14. Applications of nanotechnology for immunology10.1038/nri3488 ↗
15. Improving cancer immunotherapy through nanotechnology10.1038/s41568-019-0186-9 ↗
16. Nanotechnology for COVID-19: therapeutics and Vaccine Research10.1021/acsnano.0c04006 ↗
17. COVID-19 vaccine frontrunners and their nanotechnology design10.1021/acsnano.0c07197 ↗
18. Nanoparticle formulated vaccines: opportunities and challenges10.1039/C9NR08958F ↗
19. The role of the spleen in resistance to infection10.1146/annurev.me.37.020186.000405 ↗
20. The who, how and where of antigen presentation to B cells10.1038/nri2454 ↗
21. From the cradle to the grave: the role of macrophages in erythropoiesis and erythrophagocytosis10.3389/fimmu.2017.00073 ↗
22. Mechanisms and pathways for the clearance of bacteria from blood circulation in health and disease10.1016/j.pathophys.2016.03.001 ↗
23. Phagocytosis and oxycytosis: two arms of human innate immunity10.1007/s12026-018-8988-5 ↗
24. Of macrophages and red blood cells; a complex love story10.3389/fphys.2014.00009 ↗
25. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude10.1038/s41467-018-05079-7 ↗
26. Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator10.1161/CIRCULATIONAHA.107.750257 ↗
27. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease10.1073/pnas.1701746114 ↗
28. Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function10.1073/pnas.2002880117 ↗
29. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation10.1126/science.abb2507 ↗
30. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE210.1126/science.abb2762 ↗
31. The 2019-new coronavirus epidemic: evidence for virus evolution10.1002/jmv.25688 ↗
32. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic
33. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus)10.1016/j.dci.2014.11.018 ↗
34. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells10.1084/jem.20091181 ↗
35. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques10.1128/JVI.03309-13 ↗
36. Immune-mediated approaches against COVID-1910.1038/s41565-020-0732-3 ↗
37. Polydopamine as the antigen delivery nanocarrier for enhanced immune response in tumor immunotherapy10.1021/acsbiomaterials.9b00359 ↗
38. Bioinspired catecholic chemistry for surface modification10.1039/c1cs15026j ↗
39. The effect of polymeric nanoparticles on biocompatibility of carrier red blood cells
40. Dendritic cells and the control of immunity10.1038/32588 ↗
41. Antigen presentation and T cell stimulation by dendritic cells10.1146/annurev.immunol.20.100301.064828 ↗
42. Phagocytosis and antigen presentation in dendritic cells10.1111/j.1600-065X.2007.00552.x ↗
43. Pathogen-mimicking polymeric nanoparticles based on dopamine polymerization as vaccines adjuvants induce robust humoral and cellular immune responses10.1002/smll.201503662 ↗
44. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation10.1016/S1074-7613(00)80333-7 ↗
45. Herpes simplex virus 1 ICP22 suppresses CD80 expression by murine dendritic cells10.1128/JVI.01803-18 ↗
46. Adipocytes as anticancer drug delivery depot10.1016/j.matt.2019.08.007 ↗
47. CpG DNA induces stronger immune responses with less toxicity than other adjuvants10.1016/S0264-410X(99)00526-5 ↗
48. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery10.1016/j.vaccine.2003.09.052 ↗
49. Humoral innate immune response and disease10.1016/j.clim.2012.06.002 ↗
50. Antigen extraction and B cell activation enable identification of rare membrane antigen specific human B cells10.3389/fimmu.2019.00829 ↗
51. Regulation of the germinal center response10.3389/fimmu.2018.02469 ↗
52. Clinical characteristics of coronavirus disease 2019 in China10.1056/NEJMoa2002032 ↗
53. The trinity of COVID-19: immunity, inflammation and intervention10.1038/s41577-020-0311-8 ↗
54. The role of IFN-gamma in immune responses to viral infections of the central nervous system10.1016/S1359-6101(02)00044-8 ↗
55. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria10.4049/jimmunol.178.5.3126 ↗
56. Antiviral actions of interferons10.1128/CMR.14.4.778-809.2001 ↗
57. Potential role of interferons in treating COVID-19 patients10.1016/j.intimp.2020.107171 ↗
58. Erythrocyte-inspired delivery systems10.1002/adhm.201200138 ↗
59. Polydopamine-mediated surface modification of scaffold materials for human neural stem cell engineering10.1016/j.biomaterials.2012.06.067 ↗